Thursday, July 23, 2026

pharma · Breast Cancer · NSCLC, synchronous oligo-metastatic

Impact Therapeutics

Partner Therapeutics is a pharma organization headquartered in GB. Primary therapeutic focus areas include Breast Cancer, NSCLC, synchronous oligo-metastatic, Solid Tumors, ER-positive/HER2-negative early breast cancer,

1004, 10th Floor, Lodha Supremus Saki Vihar Road, Powai, Mumbai-400072, Maharashtra 400072, IN, Lexington HQ
2010 Founded
8 Employees
EMA registrant Type
Company details
Status
Public
HQ
1004, 10th Floor, Lodha Supremus Saki Vihar Road, Powai, Mumbai-400072, Maharashtra 400072, IN, Lexington
Founded
2010
Employees
8
Programs
12
Drugs
18
Patents
0
Clinical program

cyclophosphamide

Phase 3 · small molecule · Breast Cancer

cyclophosphamide for Breast Cancer is a Phase 3 program (small_molecule) at Partner Therapeutics Limited with 1 ClinicalTrials.gov record(s).

← All Partner Therapeutics Limited projects Phase 3 small molecule completed

Internal code CDR0000078385

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Partner Therapeutics Limited
Phase
Phase 3
Modality
small_molecule
Indication
Breast Cancer
Status
completed
Trials
1